Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.
You may also be interested in...
Bristol Boosts ImClone Funding To Accelerate Erbitux Development
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.
Bristol Boosts ImClone Funding To Accelerate Erbitux Development
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.
Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer
ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: